影响个例药品不良反应报告评价的因素

通过对影响个例药品不良反应报告评价诸如不良反应报告填写的完善程度、我国现有药品不良反应报告评价方法的局限性、联合用药、药品说明书、工作者医药学相关知识素质以及个体因素等多方面因素做一系统分析,旨在对个例药品不良反应报告评价时尽量减少干预因素的影响,以提高评价的准确性。同时对个例药品不良反应评价的重要性及其与药物警戒的关系做一简要阐述。     

药品生产企业药品不良反应监测工作探讨

目的探讨药品生产企业如何开展药品不良反应监测工作。方法分析淮南市药品生产企业不良反应监测工作现状、探讨存在问题及解决对策。结果淮南市药品生产企业2005-2008年收集上报179例ADR报表,报表数量呈逐年上升趋势。但有效收集途径以及对ADR分析、评价、处置及监测工作还不够深入。结论药品生产企业要建立考核奖惩制度、指定专人负责、加强宣传培训和信息分析利用,促进ADR监测工作深入开展。     

上市许可持有人制度下药品生产企业不良反应监测模式探讨

目的探讨上市许可持有人制度下生产企业如何开展药品不良反应监测工作,促进企业落实药品安全主体责任。方法对我国关于生产企业药品不良反应监测的相关法律法规进行梳理,结合 2015—2018年对本省企业进行药品不良反应监测实地检查情况,对我国生产企业监测现状及存在的主要问题进行分析。结果目前我国药品生产企业不良反应监测存在监测体系不健全、报告收集途径不通畅、数据利用度不高等问题。结论生产企业应通过健全内部监测体系、协助医疗机构建立 CHPS系统、建立专门的药物警戒数据库、借助“外脑”会商等措施,畅通报告收集渠道,提高自身分析评价能力,主动加强风险识别和控制,为公众用药安全提供保障。     

170例药品不良反应报告分析

我院作为全国药品不良反应重点监察医院,配合哈尔滨市卫生局对全市各医院1991.2～2002.4以来“自愿报告”的药品不良反应个例进行了收集、整理、统计、分析及资料反馈工作,现将来自33所医院170例药品不良反应报告分析如下:1 材料与方法     

简述外资制药企业在中国建立药品不良反应监测系统

《药品不良反应报告和监测管理办法》规定,制药企业是不良反应收集工作的主体,监测实践中,制药企业的药品不良反应的监测工作相对滞后,外资制药企业此方面积累了丰富的经验。本文主要介绍外资制药企业在我国建立的药品不良反应监测系统特点,希望对我国药品生产企业药品不良反应监测系统的建立有一定的参考作用。     

药品生产企业的药品不良反应监测现状与对策

<正>药品不良反应监测的目的是发现药品安全风险,采取有效措施控制风险,最大限度保障公众安全用药。药品不良反应监测是药品生产企业对药品上市后安全评价的重要手段。虽然经过几年的发展,我国药品不良反应监测工作有了长足的进步,但药品生产企业的药品不良反应监测工作仍存在较多不足。1我国药品生产企业药品不良反应监测工作现状2009年,根据国家药品不良反应监测年度报告统计显     

近年我国药品不良反应报告与监测总体情况分析

目的了解我国近年来药品不良反应报告的现状,找出存在的问题,为加强药品不良反应报告和监测管理提出建议。方法收集2010~2014年连续5年国家药品不良反应监测年度报告,采用内容分析、二次分析、对比分析等方法对药品不良反应报告情况进行了探讨。结果我国药品不良反应报告的数量逐年增加,新的和严重的药品不良反应数量较少;药品不良反应报告主体是医疗机构,药品生产经营企业的报告比例较低,抗感染药品的药品不良反应仍居首位。结论加强药品不良反应报告管理依然是业内关注的重要问题之一。建议:提高新的、严重的不良反应报告率;强化药品生产、经营企业药品不良反应报告工作;重视抗感染药品的不良反应;促进药品不良反应的信息共享。     

加强药品生产企业药品不良反应监测的思考

目的:在新版《药品不良反应(ADR)报告和监测管理办法》要求下探讨药品生产企业开展ADR监测工作存在的问题及解决对策。方法:分析药品生产企业在开展ADR监测工作中存在的问题及原因,有针对性地提出建议。结果与结论:我国应借鉴国外ADR监测经验,通过完善相关法律规定、建立ADR基金救济制度为药品生产企业提供政策保障,采取规范信息收集网络、建立ADR数据库为企业提供技术指导等措施,提高药品生产企业的ADR监测水平。     

药品生产企业如何开展药品不良反应的监测工作

药品不良反应监测是一项长期的工作,涉及广大人民群众的用药安全。我国药品生产企业众多,但作为药品不良反应监测的主体,报送的药品不良反应报告却少之又少。药品生产企业进行不良反应监测有利于新药的开发和产品质量的提高,对生产企业未来的生存发展都存在着深远的意义。     

浅议中小型药品批发企业药品不良反应的收集

本文从介绍中小型药品批发企业药品不良反应收集工作的情况入手,结合国家相关法规和企业的实际情况,指出这一类企业进行药品不良反应收集工作的问题和困难,该如何开展收集药品不良反应的工作方法进行了论述。     

我国制药企业药品不良反应报告比例偏低的原因分析

目的：促进我国制药企业的药品不良反应报告和监测,完善我国药品不良反应监测体系,促进药品安全。方法：通过国内外对比,分析我国制药企业报告比例偏低的原因。结果与结论：应树立正确的认识,完善相关法律、法规,并加强药品安全责任体系建设。     

The role of hospital and community pharmacists in pharmacovigilance

In this paper, we give an overview of the role pharmacists actually have and could have in collecting reports of adverse drug reactions (ADRs) and more widely in pharmacovigilance.In the literature, several ways are mentioned in which the pharmacist, both the community pharmacist and the hospital pharmacist, can contribute to the safe use of drugs. In addition to their responsibilities regarding drug dispensing and compliance, they can have a substantial role in ADR reporting.Especially, hospital pharmacists can play a significant role in ADR reporting because the most serious adverse drug events occur in hospitals, and ADRs account for a substantial proportion of hospital admissions.Community pharmacists, however, can also play an important role in ADR reporting. This is, for example, the case in the Netherlands where community pharmacists contribute substantially, both in numbers and in quality of ADR reports.The contribution of the pharmacist to pharmacovigilance should, however, not be limited to ADR reporting. The various pharmaceutical disciplines could also greatly enhance our understanding of the nature of ADRs. If those involved in pharmaceutical disciplines can rise to this challenge, they will significantly help deepen our insights into ADRs.     

How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers

It is surprising to see how consumer Adverse Drug Reaction (ADR) reports have been continuously increasing for the last few years in Europe. This probably results from the influence of United States (US) market where the patients feels justified in telephoning the pharmaceutical companies directly with queries regarding their treatment. The growing number of alternative sources of information (e.g. health and popular magazines, spots on radio and TV etc.) to which a consumer is exposed has added to this growth too. The changing relationship between patients and doctors may also contribute to this phenomenon. It is then interesting to evaluate the way pharmaceutical companies currently deal with consumer ADR reports. The management of consumer ADR reporting was investigated by means of a questionnaire sent to 46 French drug safety managers and drug safety officers (DSOs) of multinational pharmaceutical companies. The analysis of the survey stressed the fact that pharmaceutical companies should be prepared to face up to an increase in the number of consumer ADR reports. It clearly appears that the consumers who telephone to register side-effects should be forwarded to a trained DSO with medical or pharmaceutical background and the communication skills acquired through specific training. This person should also be able to release adequate product information validated by his/her own company. The influence of the US market seems to be changing the way pharmaceutical companies deal with consumer ADR reports. Nowadays, these reports are entered into a drug safety database by most of the companies without previously having contacted the patient's general practitioner (GP) or specialist for medical confirmation. Lastly, the drug safety managers and DSOs consulted have divided opinions about the usefulness of call centres and e-mails as tools for ADR reporting. But both tools are globally rejected by the pharmaceutical companies as a reliable means of reporting. As stated in this article, the reporting of ADRs via e-mail would cause real problems for the drug safety units. Finally, they consider that telephone call centres should be restricted to a specific communication problem such as crisis management or Dear Dr letters.     

美国制药企业不良反应报告和监测工作对我国的启示

通过介绍美国药品生产企业开展不良反应监测工作的情况并与我国医药企业进行比较,分析我国药品生产企业存在的问题与原因,并针对性地提出建议。对此,我国应该借鉴美国药品生产企业开展不良反应监测工作的经验,通过细化法规要求、扩展不良反应信息收集来源、优化内部信息传递途径、引进专业人员及完善反馈机制等举措,提高我国制药企业不良反应报告的自觉性和监测水平。     

从"齐齐哈尔第二制药有限公司假药事件"看我国的药品不良反应报告和监测制度

“齐齐哈尔第二制药有限公司假药事件”能够被迅速发现、快速报告和有效控制，建设中的药品不良反应监测体系和应急事件处理机制发挥了至关重要的作用，充分体现了国家实行药品不良反应报告和监测制度的重大意义，对于明确药品安全性监测和再评价的发展思路和方向，促进我国药品不良反应监测事业的健康可持续发展，具有重要启示和深远影响。     

我国药品不良反应责任保险的构建

目的:探索适合我国国情的药品不良反应(ADR)补偿机制。方法:结合我国实际,从保险行业、医药企业的发展以及ADR自身的发生特点等方面评价在我国将保险机制用于ADR补偿的可行性,并对ADR责任险的构建、运作提出建议。结果与结论:ADR责任险有利于保障患者的生命健康权益、解决医疗纠纷和促进医药企业的发展,并有利于促进ADR的上报和管理工作。而费率厘定、国家政策支持和ADR监测网络的完善是当前推行ADR责任险需要解决的问题。     

Pharmacovigilance in China: development and challenges

Background Rational drug use and drug safety are becoming increasingly important concerns in China with the increasing public access to drugs and the health-care system, and this has led to the development of pharmacovigilance in China. Aim of the review To provide a brief introduction about pharmacovigilance in China in terms of system development, utilization and challenges. Method Relevant studies on pharmacovigilance related to the study aim was undertaken through literature search to synthesize the extracted data. Results The creation and evolvement of China’s pharmacovigilance system spans across 30 years since 1989. The system consists of four progressing administrative layers: county, municipal, provincial and national levels. China has passed over 20 laws and regulations related to pharmacovigilance covering the processes of drug development, manufacture, distribution and use with the aim to guard drug safety. An online spontaneous self-reporting Adverse Drug Reaction (ADR) Monitoring System was established in 2003. ADRs are mainly reported by medical institutions, pharmaceutical manufacturers, and drug distributors. Currently there is no mandatory ADR reporting requirement for pharmaceutical manufacturers, and a proposed regulation under public comment will likely change this. China has started to build active pharmacovigilance surveillance programs in addition to the passive ADR reporting system. The China Food and Drug Administration has established the intensive Safety Monitoring Program and the National Adverse Drug Reaction Monitoring Sentinel Alliance Program based on electronic health records to further the efforts of ADR reporting, monitoring and analysis. Conclusion The practice of ADR monitoring and pharmacovigilance in China have made great progress. More efforts are needed both in system building, and creation of laws and regulations to strengthen the safe use of medicines.     

解析制药企业药品不良反应监测意识缺失

通过分析我国制药企业药品不良反应监测意识缺失的原因,提出相应改进建议,旨在促进我国药品生产企业药品不良反应监测工作的开展。     

部分药品企业受理消费者不良反应报告情况调查

目的：为完善和促进我国药品不良反应（ADR）监测工作提供依据。方法：随机选取500家市售企业产品,采用拨打药品生产企业包装上的联系电话方式,对企业受理消费者ADR报告情况进行调查。结果：仅有23%产品包装上的标注电话有人接听,75%企业包装上标注的电话号码无人接听,7家企业的联系方式竟然是空号。结论：企业电话接通率普遍较低,说明企业对于该渠道接受消费者ADR信息的重视程度不够。